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ABSTRACT
Purpose: To determine the feasibility of mRNAs (C-MYC, BCL-XL, BCL-6, NF-κβ, 
PTEN and AKT) in exosomes of plasma as a liquid biopsy method for monitoring and 
prognostic evolution in B-cell lymphomas.
Patients and Methods: Exosomes were isolated from 98 patients with B-cell 
Lymphoma and 68 healthy controls. mRNAs were analyzed by quantitative PCR. An 
additional 31 post-treatment samples were also studied.
Results: In the general and follicular lymphoma series, the presence of AKT 
mRNA was associated with poor response to rituximab-based treatment. Patients 
with first relapse or disease progression showed a lower percentage of PTEN and 
BCL-XL mRNA. The presence of BCL-6 mRNA was associated with a high death rate. 
The absence of PTEN mRNA in the general series, and presence of C-MYC mRNA in 
follicular lymphomas, were associated with short progression-free survival. BCL-6 and 
C-MYC mRNA were independent prognostic variables of overall survival. C-MYC mRNA 
may provide prognostic information with respect to overall survival. BCL-XL mRNA 
and increase of BCL-6 mRNA in post-treatment samples could serve as molecular 
monitoring markers.
Conclusions: This is the first large study to evaluate the prognostic and predictive 
values of pretreatment tumor-associated mRNA in exosomes. BCL-6 and C-MYC mRNA 
positivity in pretreatment samples were predictors of worse PFS compared to patients 
with mRNA negativity. C-MYC mRNA positivity was also a statistically significant 
predictor of inability to obtain complete response with first-line therapy.
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INTRODUCTION
Follicular lymphoma (FL) and Diffuse Large B-Cell 
Lymphoma (DLBCL) account for over 70% of all non-
Hodgkin Lymphomas (NHL) and rituximab is approved 
for the treatment of these common subtypes [1]. The 
identification of several lymphocyte-specific surface 
antigens has improved the possibility of developing 
effective and relatively specific targeted therapy for NHL.
The prognosis for patients with primary resistant or 
relapsed aggressive lymphomas is still poor as over 20% 
of patients with DLBCL die and 50% relapse within two 
years of diagnosis. In the case of FL, around 50% will have 
relapsed at 5 years even when treated with chemotherapy 
plus rituximab. Currently, we have no molecular prognostic 
indicators and only known clinical factors are used.
In agreement with Roschewski et al., we believe that 
assays of circulating tumor RNA/DNA could serve as “liquid 
biopsies” thereby providing information regarding response 
or resistance to treatment, in addition, this technique could 
be of use in both follicular and aggressive lymphomas [2].
Exosomes are nanovesicles not exceeding 100 
nanometers protected by a lipid-rich bound membrane. 
They develop in the cytoplasm, specifically the endoplasmic 
reticulum, in a variety of normal and pathological cells, 
including tumor cells. Their differing cells of origin 
influence their protein content, cytoplasmic or membrane 
proteins and genetic material. This genetic material can be 
used to perform liquid biopsies to analyze prognostic and 
predictive biomarkers. From a functional standpoint, this 
genetic material, mRNA and miRNA, can epigenetically 
reprogram recipient cells [3], in addition to having other 
functions related to evasion of host immune response against 
the tumor [4]. One challenge is to determine how exosomes 
work in vivo, and ascertain whether current information 
obtained from in vitro studies can be used to understand the 
mechanisms developed by exosomes within tumors.
The potential use in clinical practice of mRNA 
presence in exosomes of plasma from patients with B-Cell 
Lymphoma, which could be taken as liquid biopsies, and 
their applicability to all NHL subtypes remains to be 
defined, and especially with respect to predicting prognoses, 
response to treatment and monitoring during follow-up. In 
this study, mRNA presence of C-MYC, BCL-XL, BCL-6, 
NF-κβ, PTEN and AKT in exosomes is analyzed.
The six genes evaluated in this study have important 
roles in the deregulated pathways of many cancers, 
including lymphoid neoplasms. The PI3K/AKT/mTOR 
and NF-κβ pathways are involved in several steps of 
tumorogenesis, such as cell proliferation, survival, 
angiogenesis and tumor cell drug/radiation resistance [5–
7]. AKT regulates effectors with roles in cell survival, for 
example BCL-2 and NF-κβ, which are also dysregulated in 
B-Cell lymphomas [5]. Unfavorable clinical characteristics 
in DLBCL have been strongly associated with NF-κB 
pathway [8, 9]. In addition, PTEN is a negative regulator 
of the PI3K/AKT pathway [7]. BCL-xl expression is 
regulated by the NF-kB and AKT pathways, and rituximab 
treatment led to downregulation of BCL-XL expression by 
inhibiting NF-kB DNA-binding activity [10]. With regard 
to BCL6, this prevents apoptosis and has been reported 
to predict survival in patients with diffuse large-B-cell 
lymphoma [11]. However, in the post-rituximab era, there is 
controversy about the prognostic value of BCL6 expression 
in B-cell lymphomas. Finally, C-MYC is a potent oncogene 
which is also involved in cycle cell activation and, in 
lymphoma patients, is a predictor of more aggressive 
clinical behavior and poor response to therapy [12, 13]. On 
basis of the above, the analysis of these mRNAs in liquid 
biopsies could have both prognostic and predictive values.
RESULTS
General characteristics of patients
A total of 98 patients with follicular or diffuse large 
B-cell lymphoma were recruited for this study. Patient 
characteristics are shown in Supplementary Table 1. In 
the series studied, 53% were male, median age 60 years 
(range 26-87), 31% had B symptoms and 45% had extra 
nodal involvement. When the population was classified 
on the basis of risk factors, 26% and 27% were grouped 
into high risk (International Prognostic Index (IPI) and 
Follicular Lymphoma International Prognostic Index 
(FLIPI), respectively).
Efficacy and survival results
The overall response rate (ORR) was 93%, complete 
response (CR) was obtained in 67% patients, and 26% 
achieved partial remission (PR). After a median follow 
up of 28 months (range: 19-103 months), 18% of patients 
relapsed and 15% died.
When comparing progression-free survival (PFS) 
and overall survival (OS) between FL and DLBCL 
patients, no significant differences were found between 
these groups (Supplementary Table 2). As a result, survival 
analysis was also performed in the general series which, at 
36 month follow-up, demonstrated a PFS of 80.2% (95% 
CI, 71.4-89%) and OS of 85.2% (95% CI, 77.4-93%).
Presence of mRNA in exosomes
Exosomes were quantified by acetylcholinesterase 
activity, and were detected in plasma from DLBCL and 
FL patients. No differences in exosome levels were 
found between the lymphoma groups studied and healthy 
controls. Levels of acetylcholinesterase activity are show 
in Supplementary Figure 1. Exosome levels were not 
associated with response to treatment or patient outcomes.
The studied mRNAs were detected in exosomes in 
the following proportions: 9% for C-MYC, 16% for BCL-
XL, 34% for BCL-6, 8% for NKkB, 25% for PTEN and 
3% for AKT. BCL-6 mRNA was detected in more patient 
Oncotarget50951www.impactjournals.com/oncotarget
plasma samples than in plasma from healthy controls 
(p<0.001, χ2 test), while presence of PTEN mRNA was 
detected in more control cases (p<0.001, χ2 test). In 
addition, the frequency of positivity for BCL-6 mRNA 
in plasma was higher in DLBCL than in FL patients 
(p=0.005, χ2 test), and presence of BCL-XL was lower in 
DLBCL (p=0.024, χ2 test). The frequencies of each mRNA 
in DLBCL, FL and controls are shown in Supplementary 
Table 3. In addition, a higher number of mRNAs detected 
in the same patient was associated with a lymphoma 
subpopulation and mainly DLBCL (Supplementary 
Table 4).
mRNA in exosomes from plasma and patient 
survival
Patients with first relapse or disease progression 
during follow-up had a lower percentage of PTEN and 
BCL-XL mRNA presence in exosomes at the time of 
diagnosis (p=0.042 and p=0.049, respectively, χ2 test). 
This association with PTEN mRNA was also found in the 
DLBCL subpopulation (p=0.038, χ2 test). Data of these 
associations are showed in Table 1A. Furthermore, in the 
general series, a trend toward significant association was 
observed between the presence of BCL-6 mRNA at the 
time of diagnosis and a high patient death rate (p=0.052, 
χ2 test, Table 1B).
Progression-free survival
In the general series, the Kaplan-Meier test showed 
a trend to significant association between the absence 
of PTEN mRNA in exosomes and patients with a short 
PFS (p=0.054; Figure 1A). When the follicular series 
were analyzed alone, there was a significant association 
between the presence of C-MYC mRNA in exosomes 
and PFS (p=0.013, Kaplan-Meier test; Figure 1B). At 
36-month follow-up, PFS was 95.2% and 0% (95% CI, 
86.1-100% and 0-0%) in patients with presence of PTEN 
and C-MYC mRNA, respectively, while PFS was 74.9% 
and 82.6% (95% CI, 63.8-86.1% and 68.5-96.7%) in 
patients without. Adjusted analysis showed no associations 
between the mRNAs analyzed and PFS.
Overall survival
When the general series were analyzed, a trend 
toward significant difference was observed in OS for 
the presence of BCL-6 and C-MYC mRNA in exosomes: 
patients with these mRNAs present in plasma at diagnosis 
had shorter survival than patients without (p=0.059 and 
p=0.070, respectively, Kaplan-Meier test; Figure 2). At 
36-month follow-up, patients with BCL6 and C-MYC 
mRNA had OS of 77.1% and 60.9% (95% CI, 62.2-92% 
and 25.5-96.3%, respectively), while patients without had 
OS of 89.2% and 87.7% (95% CI, 80.2-98.2% and 80.1-
95.3%, respectively). No significant differences in OS 
were found, including in the two subpopulations, with the 
other mRNAs analyzed.
Unadjusted analysis was performed to determine the 
influence of mRNA in plasma and the clinicopathological 
parameters in OS. Clinicopathological variables that 
could be regarded as statistically supported factors in 
OS prediction were: stage, extranodal involvement, IPI, 
response to rituximab-based treatment and first relapse. 
The multivariate Cox’s regression model determined, as 
independent prognostic variables for OS, the presence 
or absence of BCL-6 or C-MYC mRNA in exosomes, 
together with occurrence of the first relapse/progression 
(Table 2A).
Exosome-related mRNA in plasma and survival in the 
series stratified according to response to treatment
As stated above, in our general series recruited 
before receiving rituximab-based treatment, 93% of the 
lymphoma patients showed complete or partial response to 
rituximab-based chemotherapy. In this series, the presence 
of AKT mRNA in exosomes was significantly associated 
with non-response to rituximab-based treatment (p=0.052, 
χ2 test). This association was also observed in the follicular 
lymphoma subpopulation (p=0.028, χ2 test), but not in 
DLBCL. Additional details are included in Table 1C.
In addition, we evaluated the prognostic value of 
mRNA in the series stratified according to response to 
treatment. In patients who responded to rituximab-base 
treatment, the presence of AKT mRNA in exosomes was 
associated with worse PFS (p=0.038). The Kaplan-Meier 
analysis also showed that presence of C-MYC and BCL-
6 mRNA correlated with worse OS in the responsive 
patient group (p=0.029 and p=0.010, respectively, Figure 
3). When the Cox’s regression models were assessed in 
stratified series, C-MYC mRNA interacted with response 
to treatment, giving a prognostic value for OS in non-
responsive patients (Table 2B).
Presence of exosome-related mRNA in plasma 
from patients after treatment with rituximab-
based chemotherapy
Our molecular variables were analyzed in exosomes 
obtained from plasma of 31 patients in our series after 
rituximab-based treatment. C-MYC mRNA was detected in 
6 post-treatment samples, BCL-XL in 3 cases, BCL-6 in 10 
and PTEN in 6; and no samples were positive for NFkB or 
AKT. Differences in the mRNA detection between pre- and 
post-treatment samples from the same patient are shown in 
Supplementary Table 5.
In this subgroup of post-treatment samples, the 
presence of BCL-XL mRNA was associated with a high 
death rate (p=0.046, χ2 test) and, when only the FL 
subpopulation was analyzed, a significant association 
was observed between the presence of BCL-6 mRNA and 
progression (p=0.047, χ2 test). More details are shown 
in Table 3A. When changes were observed between pre-
treatment and post-treatment samples, an association was 
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Table 1: Associations found between outcome of disease and evaluated mRNA in exosomes, either in total series 
(B-cells) and subpopulations (DLBCL and FL)
A PTEN (B-cells) PTEN (DLBCL) BCL-XL (B-cells)
positive negative p positive negative p positive negative p
Relapse/
Progression
 No 24.2 57.9 0.042 24.1 56.9 0.038 15.8 66.3 0.049
 Yes 1.1 16.8 0.0 19.0 0.0 17.9
B BCL-6 (B-cells)
positive negative p
Exitus
 No 26.0 59.4 0.052
 Yes 8.3 6.3
C AKT (B-cells) AKT (FL)
positive negative p positive negative p
Response to 
treatment
 Response 2.1 91.5 0.052 2.8 88.9 0.028
 Non-response 1.1 5.3 2.8 5.6
Data are shown in percentages.
Figure 1: Kaplan-Meier PFS curves in relation to presence of PTEN mRNA in total series (A) and C-MYC mRNA in FL series (B) in 
exosomes of plasma from pretreatment samples. Continuous curves show cases with mRNA absence and discontinuous curves show cases 
with mRNA presence.
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detected: new detection or increase of BCL-6 mRNA in 
post-treatment samples compared to pre-treatment samples 
was associated with non-response to treatment (p=0.038, 
χ2 test, Table 3B).
DISCUSSION
This is the first large in-vivo study to evaluate the 
prognostic implications of pretreatment tumor-associated 
exosomal mRNA. BCL-6 and C-MYC mRNA positivity 
in pretreatment samples was seen to be a statistically 
significant predictor of worsened PFS compared to 
patients with mRNA negativity. C-MYC mRNA positivity 
was also a statistically significant predictor of inability to 
obtain CR with first-line therapy.
Our work was based on a previous study [14] 
involving a different group of patients in whom we 
observed that, in lymphomas, it was feasible to identify 
the presence of exosomes in blood, and that unfavorable 
markers in plasma, mainly C-MYC mRNA, were 
associated with poor prognosis in B-cell lymphomas,. 
The latter was subsequently ratified in tissue series 
[15, 16].
We attempted to identify risk populations through 
an easily accessible source that could also be evaluated in 
evolutional terms.
Figure 2: Kaplan-Meier OS curves in relation to presence of BCL-6 (A) and C-MYC (B) mRNA in exosomes of pretreatment plasma 
samples of total series. Continuous curves show cases with mRNA absence and discontinuous curves show cases with mRNA presence.
Table 2: Multivariate Cox analysis of the association between presence of MYC and BCL-6 mRNA in exosomes and 
OS of lymphoma cancer patients (A). Statistical interaction between MYC mRNA variable and tumor pathological 
stage for predicting OS outcome value in lymphoma patients (B)
A
Variable Category HR 95% CI p value
First relapse/
Progression Yes vs No 10.862 2.672-44.159 0.001
MYC mRNA Presence vs absence 8.519 1.819-39.887 0.007
BCL-6 mRNA Presence vs absence 9.095 1.706-48.476 0.010
B
Variable Category HR 95% CI p value
RT Complete vs non-complete 7.706 2.251-26.377 0.001
RT*C-MYC mRNA RT*Presence C-MYC 9.980 1.707-58.334 0.011
RT: response to treatment
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Figure 3: Kaplan-Meier OS curves in relation to presence of C-MYC (A) and BCL-6 (B) mRNA in exosomes of pretreatment plasma 
samples from responsive patients group to rituximab-based chemotherapy. Continuous curves show cases with mRNA absence and 
discontinuous curves show cases with mRNA presence.
To date, one publication has analyzed exosome 
production and release from aggressive B-cell lymphoma 
cells in vitro and in vivo [17]. Our clinical study analyzed 
two large populations, namely follicular and diffuse 
lymphoma patients. Given that, at present, the two 
groups share overlapping treatments, at least in first-line 
treatment, we analyzed the results and found that overall 
and disease-free survival during the observation period 
were similar in both groups. This led us to analyze all 
the liquid biopsies to determine whether there were any 
common factors that linked the two groups. We believe 
that ours is the first study to analyze this question in 
patients. The results show that the presence of BCL-6 
mRNA is significantly associated with a high risk of death 
in B-cell lymphomas.
Table 3: Associations found between outcome of disease and evaluated mRNA in exosomes from post-treatment 
samples
A BCL-XL (B-cells) BCL-6 (FL)
positive negative p positive negative p
Exitus
Response to  
treatment
 No 6,5 87,1 0.046 Response 14,3 78,6 0.047
 Yes 3,2 3,2 Non-response 7,1 0
B Response to treatment
Response Non-response p
BCL-6 (B-cells)
 Absence in both samples 48.4 3.2 0.038
  Decreased in post-
treatment samples 32.3 0.0
  Increased in post-
treatment samples 9.7 6.5
Data are shown in percentages
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In our series, the data on the exosomes obtained 
from the plasma of 31 patients after undergoing treatment 
are of particular interest. In this sub-group of post-
treatment samples, the presence of BCL-XL mRNA was 
associated with a high death rate. Moreover, the presence 
of BCL-6 mRNA in post-treatment samples from patients 
who did not exhibit this mRNA in pre-treatment samples 
was associated with non-response to treatment. These 
findings stimulate thought about the value of monitoring 
molecular response and the future development of 
intensification protocols or drugs with no crossed 
resistance versus conventional treatments in patients who 
present resistance. The simple and accessible identification 
of patients with initial resistance to treatment, without 
the need for aggressive maneuvers, would provide a 
magnificent tool for future studies.
We also found a significant association between 
presence of C-MYC mRNA in exosomes and short PFS 
only in FL. A significant association was observed between 
the presence of BCL-6 mRNA in post-treatment samples 
and progression as response to treatment when only the FL 
subpopulation was analyzed. Larger series will be required 
to confirm these findings, however they open the way to 
new perspectives since they would allow better selection 
of patients who are suitable for consolidation therapies 
with radioimmunoconjugates, maintenance therapy or 
new drugs.
When we analyzed the complete series and studied 
overall survival, the presence of BCL-6 and C-MYC 
mRNA in exosomes was associated to shorter survival and 
there were no differences in the other mRNAs analyzed. 
C-MYC remained as an independent prognostic variable 
for overall survival when stratified by response.
Different immunohistochemical algorithms are 
currently being tested with varying results among patient 
series [18, 19] but, to our knowledge, there are no serum 
or exosome studies which contribute to establishing 
prognoses or monitoring response in lymphomas. Our 
study could well be even more relevant in relation to the 
determination of BCL-6 through immunohistochemistry 
despite the fact that staining results varied dramatically 
[17].
In general series, the presence of AKT mRNA in 
exosomes was associated with non-response to rituximab-
based treatment. In addition, we evaluated the prognostic 
value of mRNA in the series stratified according to 
response to treatment. In patients who responded to 
treatment, the presence of AKT mRNA in exosomes was 
associated with worse PFS. Preclinical data have been 
published that support our results, in that the inhibition 
of the AKT pathway by rituximab inhibits NFkB activity 
and the function and expression of BCL-XL. The role 
of the AKT pathway in the regulation of resistance to 
rituximab was corroborated by the use of an AKT inhibitor 
that succeeded in reversing resistance to rituximab in cell 
lines [20]. Our research also adds possible therapeutic 
relevance and we might be able to design protocols 
that incorporate AKT inhibitors that would revert any 
theoretical resistance to rituximab. Development of 
targeted agents for the treatment of DLBCL includes 
clinical evaluation of enzastaurin, an agent that suppresses 
signaling through protein kinase C and AKT pathways. 
NFkB can be inhibited indirectly with bortezomib. Some 
encouraging results were obtained in a phase II trial of 
bortezomib plus chemotherapy in patients with relapsed or 
refractory DLBCL [21]. All the above imply that there is 
an interconnection of the AKT pathways, NFkB, BCL-XL 
and PTEN in the mechanisms of resistance to rituximab.
Our research provides exosomal tumor markers 
which identify a clear population for further studies. 
One clinical application could be the design of a dose-
intensified chemotherapy clinical trial in high risk patients, 
in the middle or after standard chemotherapy. Another 
would be the assessment of response when it is not clearly 
defined in imaging tests, to select high risk patients to 
perform a biopsy. In addition, the ease and reproducibility 
of the determination means that large amounts of biopsy 
material are not required and liquid biopsies can easily 
be combined with PET-TAC to evaluate the correlation 
between this imaging technique and serum data.
MATERIALS AND METHODS
Patients and clinical characteristics
A total of 98 patients (60 DLBCL, 38 FL) were 
recruited between January 2005 and January 2011 and 
followed-up clinically until November 2014. The study 
was conducted within the GOTEL Group (details can be 
seen in the Supplementary Methods section). Samples 
were provided by the 7 participating Spanish hospitals, 
and molecular analyses were centralized in Puerta de 
Hierro University Hospital. Written informed consent 
was obtained from all participants after an explanation 
of the nature of the study as approved by the research 
ethics board of the seven hospitals. Histological diagnoses 
were ascertained by lymph node biopsy. The WHO 
Classification histological criteria were used for sample 
diagnosis and classification [22]. Clinical and laboratory 
data (supplementary methods) were available at the time 
of diagnosis.
Blood samples were taken before beginning 
treatment and, between 4-6 weeks after treatment, blood 
samples were taken from 16 DLBCL patients and 15 FL. 
Blood samples were also obtained from 68 healthy blood 
donors.
Clinical follow-up and treatment
Prospective follow-up was based on regular clinical, 
biochemical and radiological examinations, gallium scan 
and nuclear magnetic resonance or positron emission 
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tomography if recommended by radiologists. In total, 86% 
of patients received 6 cycles of R-CHOP every 21 days. 
The remaining patients received rituximab-based treatment 
with variations of this combination. Response to treatment 
was assessed on the basis of clinical, radiological and 
pathologic criteria, according to modified International 
Workshop Response Criteria Guidelines [23]. Details are 
shown in supplementary data.
Isolation and quantification of exosomes
Plasma was prepared by centrifugation of peripheral 
blood at 2,500 rpm for 25 minutes. Exosomes were isolated 
from 3 ml of plasma by differential centrifugations. To 
quantify the amount of exosomes we measured the activity 
of acetylcholinesterase. Methodological details have been 
described previously [24].
RNA extraction and real-time PCR
RNA was extracted using the mirVanaTMmiRNA 
Isolation Kit (Ambion Inc., TX) and quantified by 
NanoDrop ND-1000 (Thermo Scientific, DE). RNA was 
retro-transcribed with the Gold RNA PCR Core Kit (PE 
Applied Biosystems, CA) using random hexamers, in 
line with the manufacturer’s instructions. Real-time PCR 
was performed in duplicate in a Light-Cycler apparatus 
using the LightCycler 480 SYBR Green I Master 
Kit (Roche Diagnostics, Germany), in line with the 
manufacturer’s instructions. Additional details are shown 
in Supplementary methods and Supplementary Table 6. 
In a previous study [16], 3 common housekeeping genes 
in plasma led to erroneous normalization, which could 
have been explained by the active release mechanism of 
exosomes. For this reason, we analyzed the target mRNAs 
as presence or absence of mRNA in exosomes.
Data analysis
The clinicopathological parameters were contrasted 
with the presence of target mRNAs by the χ2 test. The 
relationship between the cumulative probability of survival, 
as well as analyzed predictors, was calculated by the Kaplan-
Meier method. Significant differences between curves were 
evaluated with Mantel’s log-rank test. To identify factors that 
might be of independent significance in influencing survival, 
the Cox proportional risk regression model was applied. Box 
plot was performed applying logarithm of data. p values 
≤0.05 were considered statistically significant. Statistical 
analysis was performed using the SPSS software, version 
14.0 (SPSS Inc. IL).
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